Reference

Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood

Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. Boms, Stefanie; Gambichler, Thilo; Freitag, Marcus; Altmeyer, Peter; Kreuter, Alexander (Department of Dermatology and Allergology, Ruhr-University Bochum, Bochum D-44791, Germany). BMC Dermatology, 4, No pp. given (English) 2004 BioMed Central Ltd. URL: http://www.biomedcentral.com/content/pdf/1471-5945-4-14. 137071-32-0 is the cas registry number. This chemical is also mentioned in this article.pdf. CODEN: BDMEC6. ISSN: 1471-5945. DOCUMENT TYPE: Journal; (online computer file) CA Section: 1 (Pharmacology) Background: Lichen sclerosus is a chronic inflammatory disease with a predilection of the anogenital region. Because of the potential side effects of repeated local application of potent glucocorticosteroids, equally-effective, safer therapeutic options are required, esp. in the treatment of children. Case presentations: We report on the efficacy of twice-daily application of pimecrolimus 1% cream in four prepubertal girls (range of age: 4 to 9 years) who suffered from anogenital lichen sclerosus. After three to four-month treatment, all patients had almost complete clin. remission including relief from itch, pain and inflammation. Only minor improvement was obsd. for the white sclerotic lesions. No significant side effects have been obsd. Conclusions: Topical pimecrolimus appears to be an effective and safe treatment for children with anogenital lichen sclerosus. The clin. benefits obsd. in the four patient presented particularly include relief of pruritus, pain and inflammation. Vehicle-controlled studies on a larger no. of patients are now warranted to substantiate our promising findings, and to investigate long-term efficacy and safety of topical pimecrolimus in anogenital lichen sclerosus. .

Method of purifying glycoside macrolides using sorption resin and suitable eluent solvents

Method of purifying glycoside macrolides using sorption resin and suitable eluent solvents. Keri, Vilmos; Czovek, Zoltan (Biogal Gyogyszergyar Rt.; Teva Pharmaceuticals USA, Inc.; Teva Gyogyszergyar Reszvenytarsasag; Csorvasi, Andrea; Rantal, Ferenc, Hung.). PCT Int. Appl. WO 2005010015 A1 3 Feb 2005, 29 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07G003-00. 53123-88-9 and 137071-32-0 which are cas registry numbers of chemicals are mentioned. ICS: C07G005-00; C07D498-18. APPLICATION: WO 2004-US24318 26 Jul 2004. PRIORITY: US 2003-PV490070 24 Jul 2003; US 2004-PV539363 26 Jan 2004. DOCUMENT TYPE: Patent CA Section: 33 (Carbohydrates) Provided is a method of purifying a macrolide, esp. tacrolimus, that includes loading macrolide onto a bed of sorption resin and eluting with a suitable eluent such as a combination of water and THF. .